<DOC>
	<DOCNO>NCT01403532</DOCNO>
	<brief_summary>The traditional therapy induction spermatogenesis male hypogonadotropic hypogonadism require HCG human menopausal gonadotropin ( HMG ) FSH pregnancy occurs . Because high cost hMG FSH preparation poor compliance , investigator raise new sequential therapeutic approach make treatment economic tolerable . The zinc supplement also evaluate patient study . This randomize , parallel , open , multi-center study compare efficacy traditional therapy new therapy evaluate safety new protocol .</brief_summary>
	<brief_title>Sequential Therapy Hypogonadotropic Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Kallmann Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Clinical hypogonadotropic hypogonadism Hormonal level : Testosterone &lt; 1.8ng/ml , LH &lt; 23 mIU/mL FSH &lt; 23 mIU/mL Infantile testis Delayed bone age Normal test anterior pituitary gland Prior therapy HMG FSH Severe dysfunction live kidney Cryptorchidism response HCG stimulation experiment ( Testosterone &lt; 1.8ng/ml HCG stimulation ) Another pituitary hormonal deficiency Hypergonadotropic hypogonadism With abnormal karyotype</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Hypogonadotropic Hypogonadism</keyword>
	<keyword>Kallmann Syndrome</keyword>
	<keyword>LH</keyword>
	<keyword>FSH</keyword>
</DOC>